BARX2 plays a negative role in regulating the canonical Wnt/β-catenin pathway [29–31] and serves as an anti-oncogene in non-small-cell lung cancer [17, 29], colorectal cancer [34], hepatocellular carcinoma [35], breast cancer [27] and ovarian cancer [28]. Here, BARX2 is linked to non-small cell lung carcinoma.